Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Researchers Produce First Widely Protective Vaccine Against Chlamydia

By McMaster University | July 20, 2016

The first steps towards developing a vaccine against an insidious sexual transmitted infection (STI) have been accomplished by researchers at McMaster University.

Researchers at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster have developed the first widely protective vaccine against chlamydia, a common STI that is mostly asymptomatic but impacts 113 million people around the world each year and can result in infertility.

In a study, recently published in the journalVaccine, the researchers show that a novel chlamydial antigen known as BD584 is a potential vaccine candidate for the most common species of chlamydia known asChlamydia trachomatis.

As most C. trachomatis infections are asymptomatic, chlamydia can often go untreated and lead to upper genital tract infections, pelvic inflammatory disease, and infertility. This is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.

“Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,” said Bulir, who just finished his PhD in medical sciences at McMaster.

“Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.”

In the research team’s study, BD584 was able to reduce chlamydial shedding – a symptom ofC. trachomatis – by 95 per cent. The antigen also decreased hydrosalpinx, another C. trachomatis symptom which involves fallopian tubes being blocked with serous fluids, by 87.5 per cent.

The results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster’s Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton’s Research Institute where the work was performed.

Co-author and McMaster PhD student, Steven Liang, explains, “not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.”

Trachoma is an eye infection caused by chlamydia and is the leading cause of preventable blindness affecting millions of people in many resource-poor regions of the world.

“The vaccine would be administered through the nose. This is easy and painless and does not require highly trained health professionals to administer, and that makes it an inexpensive solution for developing nations,” he said.

The next step is more testing for effectiveness against different strains of Chlamydia and in different formulations. The study was funded by the Canadian Institutes for Health Research.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50